Study of dupilumab administration for refractory adulthood asthma

Study of dupilumab administration for refractory adulthood asthma - Study of dupilumab administration for refractory adulthood asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038873

Enrollment

Registered

2019-12-13

Start date

2019-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with bronchial asthma in Sagamihara hospital 2. Patients who obtain written consent regarding the participation of this study

Exclusion criteria

Exclusion criteria: 1. The sensitivity to multiple drugs 2. Women who is pregnancy or breast feeding 3. Patients who joins other clinical trial study 4. Patients judged unsuitable as subjects by doctor's judgment

Design outcomes

Primary

Measure	Time frame
Change in symptom score occured 1 to 4 months after administration of dupilumab	—

Secondary

Measure	Time frame
Change in lung function test Change in inflammatory markers	—

Countries

Japan

Contacts

Public ContactYosuke Kamide

Sagamihara National Hospital Clinical Research Center for Allergy and Rheumatology

m08702012@gmail.com042-742-8311

Outcome results